Effect of tailored Helicobacter pylori eradication with platelet count recovery in immune thrombocytopenic purpura
- Conditions
- Diseases of the blood and blood -forming organs and certain disorders involving the immune mechanism
- Registration Number
- KCT0004689
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
1. Men and women over 18 years of age at the time of initial diagnosis
2. At least one positive serum anti-helicobacter antibody or urease breath test
3. Patients with platelet count 40 × 10^3 / µL or more at initial diagnosis
4. Able to read, understand and voluntarily provide written Informed Consent.
1. Age under 18 at diagnosis
2. Patients with platelet count less than 40 × 10^3 / µL at first diagnosis
3. Subjects who have previously been treated with Helicobacter pylori eradication
4. Other causes of thrombocytopenia include: autoimmune diseases, hepatitis C virus infection, liver disease, HIV infection, pseudothrombocytopenia
5. Patients taking an immunosuppressant for other disease(s)
6. Patients treated with other solid tumors when idiopathic thrombocytopenia is diagnosed
7. In the case of severe medical or surgical conditions that cannot be followed up in the future
8. Have taken proton pump inhibitors, H2RA, potassium competitive acid blocker (P-CAB), bismuth agents, non-steroidal anti-inflammatory drugs, or antibiotics within the last 4 weeks
9. Patients with history of penicillin allergies or anaphylaxis
10. If the researcher judges that participation in this study is inappropriate
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effect of tailored Helicobacter pylori eradication in platelet count recovery
- Secondary Outcome Measures
Name Time Method Helicobacter pylori eradication rate in ITP patients